Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Prana – ANA Abstract Submission NLP

October 17, 2016August 16, 2022 Kerry Rowe

final-ana-abstract-submission-nlp-4-8-16

2016

Post navigation

New data from Reach2HD trial presented at American Neurological Association Annual Meeting

Related Posts

Presentation of New Biomarker Data at Scientific Congress

September 20, 2021August 16, 2022

Prana AGM Webcast Details

November 10, 2015August 16, 2022

Parkinson’s UK Awards £150,000 to Study Prana’s PBT434

September 4, 2013August 16, 2022

Recent Posts

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson’s Disease and Movement Disorders
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
XBRL 30 June 2022 filed with the SEC
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065